Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Effectiveness and Safety of Tandospirone for Anxiety
ChiCTR2500096450Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tandospirone in anxiety disorder, sponsored by Tongji Hospital. Primary endpoint: Overall effectiveness rate of tandospirone at 3 months. Started Jan 2025; status: recruiting.
02
Drugs
tandospirone
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on ChiCTR2500096450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096450.